1500 packages of Areplivir delivered for the treatment of doctors of the Leningrad region

Promomed 25 December 2020


The Leningrad Region became the last region this year where doctors received donated 1,500 packages of medicines for coronavirus infection as part of the PROMOMED GROUP’s Areplivir for Doctors charity campaign. In total, since the launch of the All-Russian campaign in October 2020, over 11 thousand packages of the most effective and safe COVID-19 drug have been delivered for the treatment of medical workers in Moscow, Samara, Saratov, Sverdlovsk regions, the Republic of Mordovia, Perm Krai and other regions of Russia.

In the Leningrad region, the campaign event started on December 25 when the delegation of PROMOMED GROUP visited the region. During the meeting of the company's management with Deputy Head of the Leningrad Region Government Nikolai Yemelyanov and Chairman of the Health Committee Sergey Vylegzhanin, it was noted that today more than 22.4 thousand cases of COVID-19 infection have been registered in the region, a significant part of which falls on doctors of medical institutions specializing in the treatment of coronavirus infection.

According to Nikolai Yemelyanov, medical assistance to the hospitals of the region is needed today more than ever. «Thank you for helping to protect our doctors who are at the forefront of the fight against coronavirus at this difficult time. Together with socially responsible business, we will be able to defeat the epidemic faster and preserve the health of hundreds of doctors and thousands of patients,» he said. «I am sure that our meeting will lay the foundation for further cooperation.» In turn, the head of the regional Health Committee, Sergey Vylegzhanin, noted that the spread of the disease causes increased anxiety, therefore, in the current situation any support is met with gratitude. 

«We are sending a certain amount of Areplivir specifically to doctors working in red zones, medical personnel who directly treat patients with COVID-19. We believe that even one saved life of a doctor saves the lives of a much larger number of patients,» the Chief Executive Officer of PROMOMED Andrey Mladentsev explained the purpose of the program. In turn, one of the chief investigators of the clinical trials of Areplivir, Academician of the Russian Academy of Sciences, Honored Doctor of the Russian Federation Dmitry Pushkar stressed that starting therapy with the drug at an early stage of the disease allows patients with coronavirus infection to be transferred to the outpatient category. «We not only protect patients from the severe course of the disease, but also seriously reduce the burden on the entire healthcare system,» the professor noted.

At the end of the meeting, Kira Zaslavskaya, the head of the Medical Department of Promomed Group, invited the chief doctors of the Leningrad region to exchange views on the clinical use of the drug and confirmed the company's readiness to share the gained experience.

PROMOMED GROUP is the leader of the Russian pharmaceutical industry in the production of anti-infection drugs with its own research and production site Biokhimik JSC in Saransk. The company's portfolio includes more than 150 names of medicines, 80% of which are included in the list of vital and essential drugs.

Areplivir (INN: favipiravir) is the newest direct antiviral drug for the treatment of coronavirus infection; Areplivir is included in the guidelines of the Russian Ministry of Health for the treatment of COVID-19. By order of the Government of the Russian Federation, it is included in the list of vital and essential medicines. The selling price fixed by the Federal Antimonopoly Service made Areplivir one of the most affordable medicines against the SARS-CoV-2.